Articles Tagged With: brca
-
PARP Inhibitors: An Adjunct to Initial Standard Treatment for Advanced Ovarian Cancer Patients
The PRIMA study is a randomized, double-blind, multi-institutional, international phase 3 trial testing the PARP inhibitor niraparib against placebo after first-line standard treatment with platinum-based chemotherapy for newly diagnosed ovarian cancer.